EZH2-Associated Hypermethylated Gene Signature Predicts Immunotherapy Response and Implicates DUSP5 in Tumor-Immune Regulation in Triple-Negative Breast Cancer
Mingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah · 2026
Read EZH2-Associated Hypermethylated Gene Signature Predicts Immunotherapy Response and Implicates DUSP5 in Tumor-Immune Regulation in Triple-Negative Breast Cancer by Mingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13204126.txt.
Description
Mingzhan Xue and co-authors hunt a gene mark in a 2026 study of the harshest breast cancer kind. That kind lacks the three marks that guide most care, so shield drugs are a hope with few guides. A gene-silencer in the tumor may shut the genes that would let shields in.
The team sifted data for genes the silencer keeps shut and built a mark from their tags. The mark sorts who may gain from shield care. One shut gene, a brake on a swell path, stands out as a live actor in the tumor shield play. Doctors gain a mark with a tale, not just a score.
Catalog record
| CREATOR | Mingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |